GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Biora Therapeutics Inc (FRA:4ZU0) » Definitions » Revenue per Share

Biora Therapeutics (FRA:4ZU0) Revenue per Share : €0.00 (TTM As of Dec. 2023)


View and export this data going back to 2020. Start your Free Trial

What is Biora Therapeutics Revenue per Share?

Biora Therapeutics's revenue per share for the three months ended in Dec. 2023 was €0.00. Biora Therapeutics's revenue per share for the trailing twelve months (TTM) ended in Dec. 2023 was €0.00.

During the past 12 months, the average Revenue Per Share Growth Rate of Biora Therapeutics was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.

The historical rank and industry rank for Biora Therapeutics's Revenue per Share or its related term are showing as below:

During the past 6 years, Biora Therapeutics's highest 3-Year average Revenue Per Share Growth Rate was -78.60% per year. The lowest was -86.00% per year. And the median was -82.30% per year.

FRA:4ZU0's 3-Year Revenue Growth Rate is not ranked *
in the Biotechnology industry.
Industry Median: 3.7
* Ranked among companies with meaningful 3-Year Revenue Growth Rate only.

Biora Therapeutics Revenue per Share Historical Data

The historical data trend for Biora Therapeutics's Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Biora Therapeutics Revenue per Share Chart

Biora Therapeutics Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Revenue per Share
Get a 7-Day Free Trial 92.36 0.12 0.29 0.94 -

Biora Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Biora Therapeutics's Revenue per Share

For the Biotechnology subindustry, Biora Therapeutics's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Biora Therapeutics's PS Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Biora Therapeutics's PS Ratio distribution charts can be found below:

* The bar in red indicates where Biora Therapeutics's PS Ratio falls into.



Biora Therapeutics Revenue per Share Calculation

Revenue per Share is the amount of Revenue per outstanding share of the company's stock.

Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.

Biora Therapeutics's Revenue Per Share for the fiscal year that ended in Dec. 2023 is calculated as

Revenue Per Share (A: Dec. 2023 )=Revenue (A: Dec. 2023 )/Shares Outstanding (Diluted Average) (A: Dec. 2023 )
=0.004/15.773
=0.00

Biora Therapeutics's Revenue Per Share for the quarter that ended in Dec. 2023 is calculated as

Revenue Per Share (Q: Dec. 2023 )=Revenue (Q: Dec. 2023 )/Shares Outstanding (Diluted Average) (Q: Dec. 2023 )
=0/27.838
=0.00

Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was €0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Biora Therapeutics  (FRA:4ZU0) Revenue per Share Explanation

In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.

Peter Lynch categorized companies according to their revenue growth:

Slow Grower: Inflation < 10-Year Revenue Growth Rate < 10%:
Stalwart: 10% < 10-Year Revenue Growth Rate < 20%:
Fast Grower: 10-Year Revenue Growth Rate > 20%:

His favorite companies are stalwart, those growing between 10-20% a year.

Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.


Be Aware

Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.


Biora Therapeutics Revenue per Share Related Terms

Thank you for viewing the detailed overview of Biora Therapeutics's Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


Biora Therapeutics (FRA:4ZU0) Business Description

Traded in Other Exchanges
Address
4330 La Jolla Village Drive, Suite 300, San Diego, CA, USA, 92122
Biora Therapeutics Inc is a biotechnology company engaged in developing oral biotherapeutics. Its drug-device combinations could enable new treatment approaches in the delivery of therapeutics in two main areas: Targeted delivery of therapeutics to the site of disease in the gastrointestinal ("GI") tract, which is designed to improve outcomes for patients with Inflammatory Bowel Disease (IBD); and Systemic delivery of biotherapeutics, which are designed to replace injection with needle-free, oral delivery technology. Geographically, it operates only in the United States.

Biora Therapeutics (FRA:4ZU0) Headlines

No Headlines